Oral antiplatelet agents in ACS: From pharmacology to clinical differences

Fundamental and Clinical Pharmacology

Volumn 25, Issue 5, 2011, Pages 564-571

  Agewall, S ^a   Badimon, L ^b   Drouet, L ^c   Eschenhagen, T ^d   Husted, S ^e   Simon, T ^f   Steg, G ^g,h,i  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c HÔPITAL LARIBOISIÈRE   (France)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f SORBONNE UNIVERSITÉ   (France)

^g INSERM   (France)

^h UNIVERSITÉ PARIS DESCARTES   (France)

ⁱ ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Aspirin; Coronary heart disease; Platelets; Thienopyridines

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ATOPAXAR; CANGRELOR; CLOPIDOGREL; ELINOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; PAR1 RECEPTOR ANTAGONIST; PRASUGREL; PURINERGIC P2Y12 RECEPTOR ANTAGONIST; SCH 53048; TERUTROBAN; THIENOPYRIDINE DERIVATIVE; TICAGRELOR; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; CORONARY ARTERY BYPASS GRAFT; DRUG MECHANISM; HUMAN; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE FUNCTION;

ACUTE CORONARY SYNDROME; ADMINISTRATION, ORAL; BLOOD PLATELETS; CLINICAL TRIALS AS TOPIC; HUMANS; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2 RECEPTOR ANTAGONISTS; THIENOPYRIDINES;

EID: 80052900021     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2010.00890.x     Document Type: Review

References (24)

1. Bassand J.P., Hamm C.W., Ardissino D. et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur. Heart J. (2007) 28 1598-1660.
2. Van de Werf F., Bax J., Betriu A. et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur. Heart J. (2008) 29 2909-2945.
3. The Swedish RIKS HIA Report 2009.
4. Moscucci M., Fox K.A., Cannon C.P. et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur. Heart J. (2003) 24 1815-1823.
5. Eikelboom J.W., Mehta S.R., Anand S.S., Xie C., Fox K.A., Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation (2006) 114 774-782.
6. Budaj A., Eikelboom J.W., Mehta S.R. et al. Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. Eur. Heart J. (2009) 30 655-661.
7. Mehta S.R., Granger C.B., Eikelboom J.W. et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J. Am. Coll. Cardiol. (2007) 50 1742-1751.
8. Fox K.A., Bassand J.P., Mehta S.R. et al. Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes. Ann. Intern. Med. (2007) 147 304-310.
9. Gaussem P., Reny J.L., Thalamas C. et al. The specific thromboxane receptor antagonist S18886: pharmacokinetic and pharmacodynamic studies. J. Thromb. Haemost. (2005) 3 1437-1445.
10. Bousser M.G., Amarenco P., Chamorro A. et al. The Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) study: baseline characteristics of the population. Cerebrovasc. Dis. (2009) 27 608-613.
11. Wiviott S.D., Braunwald E., McCabe C.H. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. (2007) 357 2001-2015.
12. Becker R.C., Moliterno D.J., Jennings L.K. et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet (2009) 373 919-928.
13. FitzGerald G.A., Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N. Engl. J. Med. (2001) 345 433-442.
14. Mehta S., Bassand J.P., Chrolavicius S. et al. Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. Am. Heart J. (2008) 156 1080-1088.
15. Husted S., Emanuelsson H., Heptinstall S., Sandset P.M., Wickens M., Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur. Heart J. (2006) 27 1038-1047.
16. van Giezen J.J., Berntsson P., Zachrisson H., Björkman J.A. Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis. Thromb. Res. (2009) 124 565-571.
17. Gurbel P.A., Bliden K.P., Butler K. et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation (2009) 120 2577-2585.
18. Wallentin L., Becker R.C., Budaj A. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. (2009) 361 1045-1057.
19. Cannon C.P., Harrington R.A., James S. et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet (2010) 375 283-293.
20. Held C. et al. Data presented at ACC congress, March 2010.
21. Brandt J.T., Payne C.D., Wiviott S.D. et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am. Heart J. (2007) 153 e9-e16.
22. Wallentin L., Varenhorst C., James S. et al. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur. Heart J. (2008) 29 21-30.
23. Bhatt D.L., Lincoff A.M., Gibson C.M. et al. Intravenous platelet blockade with cangrelor during PCI. N. Engl. J. Med. (2009) 361 2330-2341.
24. Gurbel P.A., Bliden K.P., Butler K. et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation (2010) 121 1188-1199.